Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Tibolone

Classification: B

Drug products: Boltin, Livial, Livial®, Tibelia, Tibocina, Tibolon Aristo, Tibolon Mylan, Tibolon Orifarm

ATC code: G03CX01

Substances: tibolone

Summary

As the substance is only used by women, analyses on sex or gender differences have not been considered relevant.

Additional information

Tibolone is used as hormone replacement therapy (HRT) in estrogen deficiency syndrome in women more than one year after menopause [1,2], and as second line treatment for the prevention of osteoporosis in postmenopausal women at high risk of future fractures and with intolerance to, or contraindicated for, other medical drugs approved for the prevention of osteoporosis [1]. It is not used in the US [3].

Updated: 2017-03-31

Date of litterature search: 2016-12-20

References

Fass.se [cited 2016-12-20]. länk
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10:CD008536. PubMed
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-12-19.] Socialstyrelsens statistikdatabas

Authors: Mia von Euler, Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson